# KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Source: https://onco.cc/trials/nct03669965/  
OnCo record `nct03669965` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, run by Kartos Therapeutics, Inc., active and no longer recruiting.

## Summary

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera is a phase 2 interventional study registered as NCT03669965 by Kartos Therapeutics, Inc., with 20 participants enrolled, started 2019-01-15 and due to reach its primary completion in 2022-04. Interventions recorded: KRT-232 and Ruxolitinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03669965
- Phase: 2
- Setting: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
- Sponsor: Kartos Therapeutics, Inc.
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT03669965: https://clinicaltrials.gov/study/NCT03669965

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [KRT-232](https://onco.cc/drugs/krt-232/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)
- companies: [Kartos Therapeutics](https://onco.cc/companies/kartos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03669965.json